Toth Financial Advisory Corp decreased its holdings in shares of Stryker Co. (NYSE:SYK) by 0.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 59,210 shares of the medical technology company’s stock after selling 178 shares during the quarter. Stryker comprises approximately 2.4% of Toth Financial Advisory Corp’s investment portfolio, making the stock its 8th biggest holding. Toth Financial Advisory Corp’s holdings in Stryker were worth $12,338,000 at the end of the most recent quarter.
Several other large investors have also modified their holdings of the company. Evolution Wealth Advisors LLC grew its holdings in Stryker by 64.4% during the second quarter. Evolution Wealth Advisors LLC now owns 143 shares of the medical technology company’s stock valued at $26,000 after purchasing an additional 56 shares during the period. Balentine LLC acquired a new position in Stryker during the first quarter valued at approximately $31,000. Demars Financial Group LLC acquired a new position in Stryker during the second quarter valued at approximately $32,000. NuWave Investment Management LLC acquired a new position in Stryker during the second quarter valued at approximately $35,000. Finally, Campbell Wealth Management acquired a new position in Stryker during the second quarter valued at approximately $45,000. Institutional investors own 71.02% of the company’s stock.
In other Stryker news, CEO Kevin Lobo sold 25,855 shares of the company’s stock in a transaction on Friday, July 31st. The shares were sold at an average price of $190.80, for a total value of $4,933,134.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 6.80% of the stock is owned by insiders.
SYK has been the subject of a number of analyst reports. Needham & Company LLC restated a “hold” rating on shares of Stryker in a report on Friday, July 31st. Raymond James lifted their price target on shares of Stryker from $220.00 to $240.00 and gave the company an “outperform” rating in a research note on Monday, October 12th. Wolfe Research assumed coverage on shares of Stryker in a research note on Friday, September 11th. They issued a “market perform” rating and a $230.00 price target on the stock. Morgan Stanley lifted their price target on shares of Stryker from $215.00 to $225.00 and gave the company an “overweight” rating in a research note on Friday, July 31st. Finally, Credit Suisse Group lifted their price target on shares of Stryker from $237.00 to $243.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. Three analysts have rated the stock with a sell rating, nine have given a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $219.50.
NYSE SYK traded up $1.72 on Friday, hitting $224.05. 820,575 shares of the stock were exchanged, compared to its average volume of 1,745,606. The company has a debt-to-equity ratio of 0.93, a current ratio of 2.91 and a quick ratio of 2.12. The business’s fifty day moving average is $206.98 and its 200 day moving average is $191.07. Stryker Co. has a 52 week low of $124.54 and a 52 week high of $227.39. The company has a market capitalization of $83.98 billion, a PE ratio of 53.22, a P/E/G ratio of 3.47 and a beta of 0.83.
Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 30th. The medical technology company reported $0.64 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.02. Stryker had a net margin of 11.38% and a return on equity of 20.53%. The firm had revenue of $2.76 billion for the quarter, compared to analyst estimates of $2.63 billion. Analysts predict that Stryker Co. will post 6.29 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a $0.575 dividend. The ex-dividend date is Tuesday, September 29th. This represents a $2.30 annualized dividend and a dividend yield of 1.03%. Stryker’s dividend payout ratio is currently 27.85%.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices that are used in various medical specialties.
Featured Article: How liquidity affects the bid-ask spread
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.